These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9630998)

  • 1. Is British Biotech's Marimastat a major cancer drug?
    Davidson S
    Nat Biotechnol; 1996 Jul; 14(7):819-20. PubMed ID: 9630998
    [No Abstract]   [Full Text] [Related]  

  • 2. Marimastat (BB2516): current status of development.
    Steward WP
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S56-60. PubMed ID: 10357560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotech's uncertain present.
    Lancet; 1996 Jun; 347(9014):1497. PubMed ID: 8684093
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer.
    Shepherd FA; Giaccone G; Seymour L; Debruyne C; Bezjak A; Hirsh V; Smylie M; Rubin S; Martins H; Lamont A; Krzakowski M; Sadura A; Zee B
    J Clin Oncol; 2002 Nov; 20(22):4434-9. PubMed ID: 12431965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 6. Marimastat. BB 2516, TA 2516.
    Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
    [No Abstract]   [Full Text] [Related]  

  • 7. British Biotech and MethylGene sign agreement on Phase II antisense drug.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):6. PubMed ID: 12113069
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
    Nemunaitis J; Poole C; Primrose J; Rosemurgy A; Malfetano J; Brown P; Berrington A; Cornish A; Lynch K; Rasmussen H; Kerr D; Cox D; Millar A
    Clin Cancer Res; 1998 May; 4(5):1101-9. PubMed ID: 9607566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marimastat: the clinical development of a matrix metalloproteinase inhibitor.
    Steward WP; Thomas AL
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2913-22. PubMed ID: 11093361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
    Rosemurgy A; Harris J; Langleben A; Casper E; Goode S; Rasmussen H
    Am J Clin Oncol; 1999 Jun; 22(3):247-52. PubMed ID: 10362330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis and metastasis in colorectal cancer].
    Yamada K; Yamamura T; Yamaguchi S
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():97-101. PubMed ID: 14574863
    [No Abstract]   [Full Text] [Related]  

  • 13. Marimastat therapy as adjuvant to selective embolization in skeletal metastases of differentiated thyroid carcinoma.
    Smit JW; van Tol KM; Hew JM; Vielvoye GJ; Romijn JA; Links TP
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):421-2. PubMed ID: 11589688
    [No Abstract]   [Full Text] [Related]  

  • 14. Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition.
    Bramhall SR
    J Hepatobiliary Pancreat Surg; 1998; 5(4):392-401. PubMed ID: 9931388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorinostat.
    Grant S; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
    [No Abstract]   [Full Text] [Related]  

  • 16. [Matrix metalloproteinase inhibitors for therapy of cancer].
    Sone S; Shiraga M
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():431-7. PubMed ID: 11424420
    [No Abstract]   [Full Text] [Related]  

  • 17. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
    Richon VM; Zhou X; Rifkind RA; Marks PA
    Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
    [No Abstract]   [Full Text] [Related]  

  • 18. Matrix metalloproteinase inhibitors: present achievements and future prospects.
    Denis LJ; Verweij J
    Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AG 3340.
    Drugs R D; 1999 Feb; 1(2):137-8. PubMed ID: 10566007
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical development of metalloproteasis inhibitors in cancer therapy.
    Giavazzi R; Taraboletti G
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):53-60. PubMed ID: 11164719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.